A Standard That Can Be Corrected: Governing the Evidence in Healthy Longevity Medicine

‍

By Renée-Marie Stephano, Chief Executive Officer, Global Healthcare Accreditation

‍

In the first article in this series, I argued that longevity is the gateway and healthspan the destination. In the second, I looked at what an organization must build to connect prevention and clinical care into one system. In the third, I made the case for a standard: a clear definition of what a credible longevity medicine program is, honest treatment of evidence, boundaries around what accreditation covers, and a commitment to measuring outcomes over time.

‍

I ended that article by saying that a standard in this field should be willing to develop alongside the science and to be challenged by the people working seriously in it. That sentence raises a practical question that deserves a direct answer. Who actually decides when the standard changes? How does new evidence get in? And what stops the organizations being accredited from shaping the rules in their own favor?

‍

A standard for an emerging field can fail in two ways. It can freeze, holding organizations to yesterday’s understanding while the science moves on. Or it can drift, bending slowly toward whatever the market finds convenient. Both failures are quiet. Neither shows up in a single survey. Both erode the credibility of the accreditation and, eventually, of the field itself.

‍

This article describes how we are designing against both.

‍

The Conflict at the Center of Accreditation

‍

Every accreditor carries a structural tension, and it is better to name it than to pretend it away. The organizations being evaluated pay for the evaluation. In most areas of healthcare quality, that tension is managed through independent surveyors, published standards, and defined decision rules. In longevity medicine it is sharper, because the standard has to say something about evidence: which interventions are established, which are emerging, which are investigational, and which fall outside the scope of accreditation altogether.

‍

If the accreditor alone makes those judgments, every classification invites the question of who benefited from it. A classification that permits a lucrative intervention looks like a commercial accommodation. One that restricts it looks like an arbitrary barrier. Even when the judgment is sound, the arrangement makes it hard to believe.

‍

The answer is not a disclaimer. It is separation of function. The body that advises on the science should not be the body that decides which organizations are accredited, and the organizations being accredited should have no hand in either.

‍

A Scientific Council Drawn From Outside the Field as Well as Inside It

‍

That is the role of the Scientific Advisory Council for the Longevity Accreditation Program, which GHA has been developing forming. The Council provides scientific and clinical guidance on the standards: evaluating the evidence behind clinical practices and emerging interventions, reviewing proposed standards, advising on patient assessment and safety, identifying appropriate outcome measures, and setting out requirements for interpreting biomarkers of aging.

‍

Two design choices matter more than any others.

‍

The first is who sits on it. A council made up entirely of longevity practitioners would be the field reviewing itself, and the sector already has plenty of that. We are seeking expertise in geroscience and the biology of aging, clinical practice, evidence methodology, laboratory medicine, clinical pharmacology, research ethics and regulatory science, and patient safety. Several of those disciplines are best represented by people with no history in longevity medicine at all. An epidemiologist who has spent a career grading evidence in cardiology will ask harder questions about an aging biomarker than someone whose practice depends on it. That outside discipline is a large part of why the Council’s guidance should be believed.

‍

The second is how conflicts are handled. Almost everyone qualified to advise on longevity science has some commercial exposure to it, through research funding, advisory roles, or clinical practice. A rule that excluded all of them would produce an empty council or one without standing. The approach we have taken is disclosure and recusal. Members disclose their affiliations, roles, and financial interests, and step aside from matters that involve their own organizations.

‍

The Council advises; it does not accredit. Decisions about whether a particular organization meets the standards remain within GHA’s separate accreditation process. I believe that boundary is what makes the role acceptable to serious scientists. Asking an academic to decide which clinics pass is asking them to take responsibility for commercial outcomes they cannot supervise. Asking them to tell us what the evidence supports, and to tell us plainly when the standard has it wrong, is a different and far more appropriate request.

‍

Opening the Standard to Review

‍

A Council, however well composed, is still a small group, and standards written by small groups reflect the assumptions of the people in the room. So alongside the Council, we have opened the standard itself to structured review.

‍

The Living Standard is an open expert review of GHA’s Healthy Longevity Medicine Standard, conducted with the Longevity Vanguard. It invites clinicians, researchers in gerontology and biogerontology, and the biology of aging, and specialists in evidence methods, laboratory medicine, ethics, and health policy to respond to the standard in manageable sections. Participants receive a short online questionnaire every few weeks, each taking about ten minutes. Responses are confidential and reported only in aggregate.

‍

Two commitments define it. The aggregate results will be published. So will any changes we make to the standard in response. The second commitment is the one that matters most. Consultation without a record of what changed is a courtesy. Consultation with a published record is accountability, because anyone can then see where expert opinion moved the standard and where it did not, and judge our reasons for themselves.

‍

We are beginning with the questions we have found hardest to settle ourselves. How strong does the evidence for an intervention need to be before it can be offered at all, rather than simply offered with disclosure? Where should the boundary of accreditation sit for interventions outside the current evidence base? How should measures of biological age be reported to patients, given what they can and cannot yet tell us? These are not questions an accreditor should answer alone, and they are not questions the field has answered yet.

‍

Evidence From Practice, Not Only From the Literature

‍

The third piece responds to a problem I raised in the previous article. If healthspan is the objective, the field has to get better at measuring whether care is delivering it. Today each clinic monitors its own outcomes in its own way, which produces many datasets that cannot be compared and very little shared knowledge.

‍

The GHA Living Evidence Registry is designed to begin addressing that. It is a quality and safety registry that records the same core information, in the same way, about patients of participating GHA-accredited longevity clinics. The founding pilot is planned with three accredited providers in one region, each enrolling consecutive eligible adults who are beginning a new outpatient longevity program. Consecutive enrollment matters. Every eligible patient is invited, so the registry reflects routine care rather than a clinic’s best cases.

‍

The registry begins with five measures, collected at the start of care and at a follow-up about ninety days later. Whether a baseline assessment, a goal chosen by the patient, and a physician-approved care plan are documented within fourteen days. Whether necessary information reaches the next treating clinician, including a home clinician after a patient travels for care. Whether follow-up happens within the planned window. How patients describe their progress toward the goal they chose. And whether the clinic asks about and records problems, unplanned care, or treatment stopped because of a problem.

‍

Those measures may look modest. They are deliberately so. In the second article in this series I argued that integrated care breaks at the handoffs, and that an organization unable to see what happens after a patient leaves cannot honestly claim to be built for healthspan. The registry measures exactly those points. It is the operational argument of this series turned into data.

‍

I also want to be clear about what the registry will not do. It will not prove that longevity interventions work. An observational registry describes care processes, progress as patients report it, and safety follow-up. It can help clinics improve and can point to questions worth studying properly, but it cannot show that a treatment caused a health improvement or extended anyone’s life. Saying so plainly at the outset is part of what separates a quality registry from a marketing claim.

‍

The governance follows the same separation as the Council. Patient identifiers stay with the treating clinic, and GHA receives only coded information under a written data agreement. Participating clinics receive private feedback on their own care. The registry does not rank clinics, GHA does not sell patient-level data, and any public report will show only reviewed aggregate results, with small numbers suppressed to protect privacy. Taking part does not affect accreditation decisions. The Scientific Advisory Council will oversee how the registry’s information is defined, checked, and reported, and the final measures and timing will be confirmed through that review before enrollment begins.

‍

How the Pieces Fit Together

‍

Taken separately, each of these is useful. Together they form a loop.

‍

The Council advises on what the evidence supports and how the standard should classify it. The Living Standard tests the text of the standard against the judgment of a much wider expert community, and publishes the result. The registry shows what actually happens to patients under the standard in routine practice. Findings from all three return to GHA’s established standards development process, where proposed changes are reviewed before they are adopted. Nothing changes automatically, and nothing changes in private.

‍

That is what I mean by a standard that can be corrected. It does not depend on getting every judgment right in its first version. It depends on having a visible, disciplined way to find out where it is wrong and to fix it.

‍

What This Asks of the Organizations We Accredit

‍

This approach makes demands on accredited organizations that a fixed checklist would not. Requirements will change as the evidence changes, and an intervention classified one way today may be classified differently after the next review. Organizations will be asked to disclose the level of evidence to patients, to contribute to shared measurement, and to accept that the standard they were surveyed against is not the last word.

‍

I expect the organizations most likely to lead this field to welcome that. A clinic that is confident in its care has little to fear from consistent measurement and a great deal to gain from a credential the scientific community can take seriously. An organization that needs the rules to stand still is making a different kind of bet about its own practice.

‍

Where the Work Stands

‍

The Scientific Advisory Council is being formed now, and we are inviting scientists, clinicians, and quality professionals to express interest in Council membership, technical review, and surveyor faculty. The Living Standard is open to applicants. The Living Evidence Registry has not yet begun enrolling patients; its measures and timing will be confirmed through scientific review first, and we are in conversation with accredited providers interested in the founding pilot.

‍

I would rather describe this work honestly at an early stage than present it as finished. The field is young, the evidence is moving, and the credibility of any standard will rest on how it behaves when it is challenged.

‍

In a mature field, trust in a standard comes from its history. In a new one, it has to come from its design. A standard for healthy longevity medicine earns trust not by claiming to be right on the first day, but by showing, in public, how it will find out when it is not.

‍

Renée-Marie Stephano is Founder and Chief Executive Officer of Global Healthcare Accreditation and co-founder of the Longevity Vanguard, an invitation-only coalition that brings together longevity clinics, the companies that serve them, and the employers, insurers and investors who buy from them. A recognized standard setter in medical tourism, she co-developed the Medical Tourism Index and now leads GHA’s work in longevity and regenerative medicine accreditation. She has spoken at more than 100 events and has been featured in more than 250 publications. Learn more about the Longevity Vanguard.

‍